BIORCE Company Profile

Background

Overview: BIORCE is a Barcelona-based TechBio company founded in 2024, dedicated to revolutionizing drug development through artificial intelligence (AI). The company's mission is to accelerate medical advancements and improve patient outcomes by enhancing the efficiency and accessibility of clinical trials. BIORCE's flagship product, Jarvis, is an AI-driven clinical assistant designed to streamline the planning, execution, and optimization of clinical studies.

Key Strategic Focus

Core Objectives:

Integrate AI to address inefficiencies in clinical trials.

Enhance data accessibility for healthcare professionals.

Reduce the time and cost associated with drug development.

Specialization Areas:

AI-driven protocol design.

Feasibility analysis.

Site selection.

Patient recruitment.

Key Technologies:

Advanced AI algorithms for data analysis.

Machine learning for trend identification.

Optimization tools for clinical trial parameters.

Target Markets:

Pharmaceutical companies.

Clinical research organizations.

Healthcare providers involved in clinical trials.

Financials and Funding

Funding History:

November 2024: BIORCE secured €3.5 million in funding to accelerate the development of Jarvis.

Investors:

YZR Capital.

Mustard Seed Maze.

Outsized Ventures.

Pathena Family Office.

Plug and Play Tech Center.

Utilization of Capital:

Enhancing the AI capabilities of Jarvis.

Expanding data integration features.

Improving user interface and experience.

Pipeline Development

Jarvis Development Milestones:

Q1 2025: Integration of additional clinical trial databases.

Q2 2025: Launch of advanced optimization tools for protocol design.

Q3 2025: Implementation of real-time feasibility analysis features.

Technological Platform and Innovation

Proprietary Technologies:

Jarvis: An AI assistant leveraging a database of over 500,000 studies to provide solutions for protocol design, feasibility analysis, site selection, and patient recruitment.

Scientific Methodologies:

Advanced search algorithms.

Trend identification.

Comparative analysis across extensive clinical trial databases.

AI-Driven Capabilities:

Optimization of inclusion/exclusion criteria.

Sample size determination.

Dosage prediction.

Leadership Team

Pedro Coelho: Co-Founder & Chief Executive Officer.

Clara Bernardes: Co-Founder & Head of Clinical.

Competitor Profile

Market Insights and Dynamics:

The clinical trial industry is experiencing a shift towards AI integration to enhance efficiency and reduce costs.

The global clinical trials market is projected to grow significantly, driven by technological advancements and increasing demand for personalized medicine.

Competitor Analysis:

Klineo (France): Simplifies the process of finding and participating in clinical trials by connecting patients and healthcare providers.

Hawthorne Effect (USA): Decentralizes clinical trials, maximizing accessibility and data integrity through licensed healthcare professionals and connected technology.

Biolexis Therapeutics (USA): Utilizes a proprietary platform combining fragment screening and machine learning to expedite drug candidate development.

Strategic Collaborations and Partnerships

BIORCE has established partnerships with various clinical research organizations and healthcare providers to integrate Jarvis into existing workflows, enhancing data accessibility and trial efficiency.